These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Deferasirox. Stumpf JL. Am J Health Syst Pharm; 2007 Mar 15; 64(6):606-16. PubMed ID: 17353569 [Abstract] [Full Text] [Related]
9. Clinical application of deferasirox: practical patient management. Vichinsky E. Am J Hematol; 2008 May 15; 83(5):398-402. PubMed ID: 18058997 [Abstract] [Full Text] [Related]
10. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D. Cochrane Database Syst Rev; 2010 Aug 04; (8):CD007477. PubMed ID: 20687088 [Abstract] [Full Text] [Related]
12. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A, EPIC Study Investigators. Haematologica; 2010 Apr 04; 95(4):557-66. PubMed ID: 19951979 [Abstract] [Full Text] [Related]
16. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B, study CICL670A2201 investigators. Am J Hematol; 2013 Dec 04; 88(12):1068-73. PubMed ID: 23946212 [Abstract] [Full Text] [Related]
17. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Inati A, Kahale M, Sbeiti N, Cappellini MD, Taher AT, Koussa S, Nasr TA, Musallam KM, Abbas HA, Porter JB. Pediatr Blood Cancer; 2017 Jan 04; 64(1):188-196. PubMed ID: 27576370 [Abstract] [Full Text] [Related]
19. Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study. Piga A, Longo F, Origa R, Roggero S, Pinna F, Zappu A, Castiglioni C, Cappellini MD. Br J Haematol; 2014 Nov 04; 167(3):423-6. PubMed ID: 24976388 [No Abstract] [Full Text] [Related]